Mesothelioma: Time to Take Stock

Health and Safety Executive. Mesothelioma. [www.hse.gov.uk/statistics/causdis/meso.htm]

Toms J.R. , ed. CancerStats Monograph 2004. London: Cancer Research UK, 2004

Hodgson J.T. , McElvenny D.M. , Darnton A.J. , Price M.J. , Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587–93

Peto J. , Decarli A. , La Vecchia C. , Levi F. , Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666–72

Peto J. , Hodgson J.T. , Matthews F.E. , Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535–9

[www.legislation.hmso.gov.uk] 2005

LaDou J. , Landrigan P. , Bailar J.C. III , Foa V. , Frank A. A call for an international ban on asbestos. Can Med Assoc J 2001; 164: 489–90

Guidotti T.L. The debate on banning asbestos. Can Med Assoc J 2001; 165: 1189–90

Butchart E.G. , Ashcroft T. , Barnsley W.C. , Holden M.P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976; 31: 15–24

Treasure T. , Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004; 364: 1183–5

Weder W. , Kestenholz P. , Taverna C. . Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004; 22: 3451–7

Ryan C.W. , Herndon J. , Vogelzang N.J. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113(1 suppl): 66S–73S

Berghmans T. , Paesmans M. , Lalami Y. . Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111–21

Vogelzang N.J. , Rusthoven J.J. , Symanowski J. . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–44

Armato S.G. III , Oxnard G.R. , MacMahon H. . Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 2004; 31: 1105–15

Boutin C. , Rey F. , Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754–8

Graaf-Strukowska L. , van der Z.J. , van Putten W. , Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura—a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999; 43: 511–16

Rusch V.W. , Rosenzweig K. , Venkatraman E. . A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788–95

Forster K.M. , Smythe W.R. , Starkschall G. . Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 2003; 55: 606–16

Soysal O. , Karaoglanoglu N. , Demiracan S. . Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997; 11: 210–13

Sugarbaker D.J. , Flores R.M. , Jaklitsch M.T. . Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54–63

Tan C. , Swift S. , Gilham C. , Shaefi S. . Survival in surgically diagnosed patients with malignant mesothelioma in current practice. Thorax 2002; 57: iii36

Aziz T. , Jilaihawi A. , Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002; 22: 298–305

Stephens R. The dangers of subgroup analysis. Lancet Oncol 2001; 2: 9

Robinson B.W. , Creaney J. , Lake R. . Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612–16